Drug Approval | May 29, 2025
Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Bayer expects 2025 to be the most difficult year of its turnaround
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Subscribe To Our Newsletter & Stay Updated
